These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 33857539

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W, Tantichattanon W, Wongwatcharapaiboon S, Treeratweeraphong V.
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [Abstract] [Full Text] [Related]

  • 23. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F, Quentin C.
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [Abstract] [Full Text] [Related]

  • 24. Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
    Bail L, Ito CAS, Arend LNVS, Nogueira KDS, Tuon FF.
    Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115568. PubMed ID: 34749296
    [No Abstract] [Full Text] [Related]

  • 25. Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
    Meschiari M, Faltoni M, Kaleci S, Tassoni G, Orlando G, Franceschini E, Burastero G, Bedini A, Serio L, Biagioni E, Melegari G, Venturelli C, Sarti M, Bertellini E, Girardis M, Mussini C.
    Int J Antimicrob Agents; 2024 May; 63(5):107134. PubMed ID: 38453094
    [Abstract] [Full Text] [Related]

  • 26. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.
    Karakonstantis S, Kritsotakis EI, Gikas A.
    Infection; 2020 Dec; 48(6):835-851. PubMed ID: 32875545
    [Abstract] [Full Text] [Related]

  • 27. Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae.
    Tüzemen NÜ, Önal U, Merdan O, Akca B, Ener B, Özakın C, Akalın H.
    Sci Rep; 2024 Jul 30; 14(1):17567. PubMed ID: 39080317
    [Abstract] [Full Text] [Related]

  • 28. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H, Poulakou G.
    Drugs; 2009 Oct 01; 69(14):1879-901. PubMed ID: 19747006
    [Abstract] [Full Text] [Related]

  • 29. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
    Savoldi A, Carrara E, Piddock LJV, Franceschi F, Ellis S, Chiamenti M, Bragantini D, Righi E, Tacconelli E.
    BMC Infect Dis; 2021 Jun 09; 21(1):545. PubMed ID: 34107899
    [Abstract] [Full Text] [Related]

  • 30. Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria.
    Wang Y, Feng J, Yu J, Wen L, Chen L, An H, Xiao W, Zhang B, Feng H, Zhou M, Jiang Z.
    Ann Clin Microbiol Antimicrob; 2024 Jul 04; 23(1):60. PubMed ID: 38965559
    [Abstract] [Full Text] [Related]

  • 31. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F.
    J Antimicrob Chemother; 2004 Dec 04; 54(6):1085-91. PubMed ID: 15546972
    [Abstract] [Full Text] [Related]

  • 32. In Vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa.
    Asempa TE, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2019 Sep 04; 63(9):. PubMed ID: 31262769
    [Abstract] [Full Text] [Related]

  • 33. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS, Loeb M, Leto D, Brooks AA.
    Postgrad Med; 2020 Apr 04; 132(3):234-250. PubMed ID: 31608743
    [Abstract] [Full Text] [Related]

  • 34. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R, Bakthavatchalam YD, Nadarajan A, Dwarakanathan HT, Venkatasubramanian R, Veeraraghavan B.
    Eur J Clin Microbiol Infect Dis; 2021 Mar 04; 40(3):461-475. PubMed ID: 33009595
    [Abstract] [Full Text] [Related]

  • 35. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR, Bowker KE, Attwood M, MacGowan AP.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2411-2417. PubMed ID: 30020472
    [Abstract] [Full Text] [Related]

  • 36. Treatment Options for Carbapenem- Resistant Gram-Negative Infections.
    Fritzenwanker M, Imirzalioglu C, Herold S, Wagenlehner FM, Zimmer KP, Chakraborty T.
    Dtsch Arztebl Int; 2018 May 21; 115(20-21):345-352. PubMed ID: 29914612
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis.
    Onorato L, Di Caprio G, Signoriello S, Coppola N.
    Int J Antimicrob Agents; 2019 Dec 21; 54(6):735-740. PubMed ID: 31479738
    [Abstract] [Full Text] [Related]

  • 38. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of Pseudomonas aeruginosa.
    Mataraci Kara E, Yilmaz M, İstanbullu Tosun A, Özbek Çelik B.
    Infect Dis (Lond); 2020 Sep 21; 52(9):616-624. PubMed ID: 32427010
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z, Kayacan C, Oncul O.
    Int J Antimicrob Agents; 2012 Jan 21; 39(1):86-9. PubMed ID: 22041508
    [Abstract] [Full Text] [Related]

  • 40. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD, Hsu AJ.
    J Pediatric Infect Dis Soc; 2019 Jul 01; 8(3):251-260. PubMed ID: 30793757
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.